Personalized vaccine plus chemo cocktail aims to outsmart advanced ovarian cancer

NCT ID NCT02432378

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This trial tests whether adding a personalized vaccine and immune-boosting drugs to standard chemotherapy can help the body fight advanced ovarian cancer more effectively. Participants receive chemotherapy directly into the abdomen along with oral medication and injections of a vaccine made from their own immune cells. The study measures changes in immune cell activity and tumor response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Cisplatin, celecoxib, interferon-alpha, rintatolimod, and autologous alpha-DC1 vaccine
What this could lead to
If successful, this approach could improve immune response and increase the chance of complete tumor clearance in advanced ovarian cancer.
What could go wrong
This is an early-phase trial with a small number of participants, so results may not apply broadly. The combination therapy may cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED STAGE EPITHELIAL OVARIAN CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hillman Cancer Center

    Pittsburgh, Pennsylvania, 15232, United States

  • UPMC CancerCenter at Magee-Womens Hospital of UPMC

    Pittsburgh, Pennsylvania, 15213, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.